Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy

Bibliographys

• HORNYKIEWICZ 0: Biochemical aspects of Parkinson's disease. Neurology (1998) 51:S2–S9.
   PubMed Web of Science ®Google Scholar
• NUTT JG: Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Exp. NeuroL (2003) 184:9–13.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of PD treatment.
   Google Scholar
• SAMII A. LETWIN SR, CALNE DB: Prospects for new drug treatment in idiopathic parkinsonism. Drug Discov. Today (1998) 3:131–140.
   Web of Science ®Google Scholar
• KURTH MC, ADLER CH: COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology (1998) 50:S3–14.
   PubMedGoogle Scholar
• LEWITT PA: New drugs for the treatment of Parkinson's disease. Pharmacotherapy (2000) 20:26S–32S.
   Google Scholar
• LUDIN HP: [Modern therapeutic possibilities in Parkinson's disease]. Schweiz Med. Wochenschr. (1999) 129:741–747.
   PubMedGoogle Scholar
• MANNISTO PT, ULMANEN I, LUNDSTROM K et aL: Characteristics of catechol 0-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res. (1992) 39:291–350.
   PubMedGoogle Scholar
• NUTT JG: Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet (1998) 351:1221–1222.
   PubMed Web of Science ®Google Scholar
• GOMES P, SOARES-DA-SILVA P: Interaction between L-DOPA and 3-0-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology (1999) 38:1371–1380.
   PubMed Web of Science ®Google Scholar
• RECHES A, MIELKE LR, FAHN S: 3-0-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology (1982) 32:887–888.
   PubMed Web of Science ®Google Scholar
• DUPONT E, BURGUNDER JM, FINDLEY LJ, OLSSON JE, DORFLINGER E: Tolcapone added to levodopa in stable parkinsonian patients: a double- blind placebo-controlled study. Tolcapone in Parkinson's disease Study Group II (TIPS II). Mov. Disord. (1997) 12:928–934.
   Google Scholar
• KAAKKOLA S, GORDIN A, MANNISTO PT: General properties and clinical possibilities of new selective inhibitors of catechol 0-methyltransferase. Gen. Pharmacol. (1994) 25:813–824.
   PubMedGoogle Scholar
• KAAKKOLA S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs (2000) 59:1233–1250.
   PubMed Web of Science ®Google Scholar
• •Important review on COMT inhibitors.
   Google Scholar
• ROBERTS JW, CORA-LOCATELLI G, BRAVI D et al.: Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 43:2685–2688.
   PubMed Web of Science ®Google Scholar
• SPENCER CM, BENFIELD P: Tolcapone. CNS Drugs (1996) 5:475–481.
   Web of Science ®Google Scholar
• WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long- term treatment. The Tolcapone Stable Study Group. Neurology (1997) 49:665–671.
   PubMed Web of Science ®Google Scholar
• GORDIN A. REINIKAINEN K, DURIF F: Effect of entacapone on quality of life in Parkinson's disease. J. Am. Geriam. Soc. (2001) 49:S123–S123.
   Web of Science ®Google Scholar
• DURIF F, DEVAUX I, PERE JJ, DELUMEAU JC, BOURDEIX I: Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur. NeuroL (2001) 45:111–118.
   PubMed Web of Science ®Google Scholar
• ASSAL F, SPAHR L, HADENGUE A et al.: Tolcapone and fidminant hepatitis. Lancet (1998) 352:958.
   PubMed Web of Science ®Google Scholar
• SPAHR L, RUBBIA-BRANDT L, BURKHARD PR, ASSAL F, HADENGUE A Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig. Dis. Sci. (2000) 45:1881–1884.
   PubMed Web of Science ®Google Scholar
• COLOSIMO C: The rise and fall of tolcapone. J. NeuroL (1999) 246:880–882.
   PubMed Web of Science ®Google Scholar
• OLANOW CW: Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch. NeuroL (2000) 57:263–267.
   PubMed Web of Science ®Google Scholar
• •Detailed appraisal of tolcapone hepatotoxicity by a panel of experts.
   Google Scholar
• NO AUTHORS LISTED: European Medicine Evaluation Agency: Recommendation for the suspension of the marketing authorization for Tasmar® (tolcapone). Press Release (1998)
   Google Scholar
• NO AUTHORS LISTED: European Medicine Evaluation Agency: EMEA Public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar®). Press Release (2004)
   Google Scholar
• ELLISON RH: Dear Healthcare Professional letter regarding appropriate use of Tasmar®. Roche Laboratories Inc. (1998).
   Google Scholar
• NO AUTHORS LISTED: New warnings for Parkinson's drug, Tasmar. Food and Drug Administration Talk Paper (1998).
   Google Scholar
• BENABOU R, WATERS C: Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert. Opin. Drug Sal: (2003) 2:263–267.
   PubMedGoogle Scholar
• •Recent and detailed review on tolcapone hepatotoxicty.
   Google Scholar
• BORGES N: Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Sal: (2003) 26:743–747.
   PubMed Web of Science ®Google Scholar
• NISSINEN E, KAHEINEN P, PENTTILA KE, KAIVOLA J, LINDEN IB: Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. (1997) 340:287–294.
   PubMed Web of Science ®Google Scholar
• •Seminal paper on the mechanisms of tolcapone toxicity.
   Google Scholar
• HAASIO K, KOPONEN A. PENTTILA KE, NISSINEN E: Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. (2002) 453:21–26.
   Google Scholar
• HAASIO K, LOUNATMAA K, SUKURA A Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo. Exp. ToxicoL PathoL (2002) 54:9–14.
   PubMed Web of Science ®Google Scholar
• HAASIO K, NISSINEN E, SOPANEN L, HEINONEN EH: Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J. Neural Transm. (2002) 109:1391–1401.
   PubMed Web of Science ®Google Scholar
• KORLIPARA LV, COOPER JM, SCHAPIRA AH: Differences in toxicity of the catechol- 0-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells. Neuropharmacology (2004) 46:562–569.
   PubMed Web of Science ®Google Scholar
• HAASIO K, SOPANEN L, VAALAVIRTA L, LINDEN IB, HEINONEN EH: Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J. Neural Transm. (2001) 108:79–91.
   PubMed Web of Science ®Google Scholar
• SMITH KS, SMITH PL, HEADY TN et al.: In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol (2003) 16:123–128.
   PubMed Web of Science ®Google Scholar
• WIKBERG T, VUORELA A. OTTOILA P, TASKINEN J: Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. (1993) 21:81–92.
   PubMed Web of Science ®Google Scholar
• ACUICIA G, FOERNZLER D, LEONG D et al.: Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. (2002) 2:327–334.
   PubMedGoogle Scholar
• ••Elegant approach to the problem of tolcapone hepatotoxicity.
   Google Scholar
• FISHER A, CROFT-BAKER J, DAVIS M, PURCELL P, MCLEAN AJ: Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov. Disord. (2002) 17:1362–1365.
   PubMed Web of Science ®Google Scholar
• BECK S, HUBBLE J, REINIKAINEN K: Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov. Disord. (2002) 17:1397–1399.
   PubMed Web of Science ®Google Scholar
• ONOFRJ M, THOMAS A, IACONO D, DI IORIO A, BONANNI L: Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol (2001) 46:11–16.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, CLEGG k Entacapone asan adjunctive treatment to levodopa in Parkinson's disease. Wessex Institute for Health Research and Development. Development and Evaluation Committee Report No. 104 (1999).
   Google Scholar